Navigation Links
Oramed Pharmaceuticals Moves Forward with Investigational New Drug Application for Oral Insulin
Date:2/14/2013

JERUSALEM, February 14, 2013 /PRNewswire/ --

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that it has been in communication with the U.S. Food and Drug Administration (FDA) regarding its Investigational New Drug (IND) application for oral insulin. The FDA has asked Oramed to perform a sub study in a controlled in-patient setting for up to a one-week period. In order to accommodate the FDA's request, Oramed will submit a new IND with a clinical protocol for the aforementioned sub study.

"We are very pleased to be in close and positive communications with the FDA, as well as having a clear path which meets the FDA's input. This positions us for imminent clearance from the FDA to proceed with our planned clinical studies," commented Nadav Kidron , CEO of Oramed.  

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed's technology is based on over 30 years of research by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801) currently approaching Phase 2 clinical trials under U.S. IND, and with its oral exenatide capsule (ORMD-0901; a GLP-1 analog), currently approaching Phase 2a trials. The company's corporate and R&D headquarters are based in Jerusalem.

For more information, the content of which is not part of this press release, please visit  http://www.oramed.com
'/>"/>

SOURCE Oramed Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Bioassociate Announces Initiation of Coverage on Oramed Pharmaceuticals, Inc.
2. Oramed Pharmaceuticals Announces Reverse Stock Split
3. Oramed Pharmaceuticals Granted 2nd Patent in New Zealand; 3rd Patent for Core Technology on Oral Delivery of Proteins
4. Auxilium Pharmaceuticals, Inc. to Present at the Leerink Swann Global Healthcare Conference
5. Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2012 Results and Conduct Conference Call on Tuesday, February 26, 2013
6. Keryx Biopharmaceuticals to Present at the 15th Annual BIO CEO & Investor Conference Presentation Scheduled for Monday, February 11th at 2:30 PM ET
7. DelMar Pharmaceuticals Announces Acquisition and $5.4 Million Private Placement to Advance Novel Cancer Therapies
8. Todays Research on Mylan and Watson Pharmaceuticals: One Drug Makers Sorrow is Another Ones Joy
9. Biscayne Pharmaceuticals Closes $1.5 Million Financing To Advance Recent Discoveries Of Pioneering Endocrine Drug Researcher
10. UPM Pharmaceuticals Enhances its Pre-Formulation Capabilities
11. Biosim Pharmaceuticals, Manufacturers of Generic ACTHAR, to Participate at Biotech Showcase 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... November 25, 2014 Miles Holder, formerly ... the Graphel Carbon Products team as Sales/Marketing Manager. Mr. ... and customer service for the graphite industry. , “We ... our team,” stated Dave Trinkley, VP of Market and ... range of experience in the graphite industry, along with ...
(Date:11/26/2014)... N.J. and WILMINGTON, DE (PRWEB) November 26, 2014 ... 2nd Annual MPN Heroes recognition reception on December 5, ... of Hematology’s annual meeting. The MPN Heroes event will ... contributions in the field of myeloproliferative neoplasms (MPNs). ... show "Nashville," will discuss his family's cancer journey at ...
(Date:11/26/2014)... Theravalues Corporation est fier d,annoncer le ... au salon Hi Europe 2014 (du 2 au ... Curcumine la plus biodisponible actuellement sur le ... des ingrédients approuvés par les règlements européens. ... dans la racine de curcuma ( Curcuma longa ...
(Date:11/26/2014)... /PRNewswrie/ -- Theravalues Corporation annuncia con orgoglio il lancio ... di Hi Europe 2014 (dal 2 al 4 dicembre, ... della curcumina con la maggiore biodisponibilità di sempre, con ... approvati dalle norme europee. La curcumina è ... ( Curcuma longa ) che è stata associata con ...
Breaking Biology Technology:Miles Holder Joins Graphel Corporation as Sales/Marketing Manager 2CURE Magazine and Incyte to Honor MPN Heroes 2CURE Magazine and Incyte to Honor MPN Heroes 3CURE Magazine and Incyte to Honor MPN Heroes 4La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 3La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 3
... March 1, 2012  Berg Diagnostics, a Boston-based ... Laboratory Licensure and Certificate of Registration from ... under the Clinical Laboratory Improvement Amendment (CLIA).  ... ) "The achievement of a ...
... CITY, Calif., March 1, 2012 Incline Therapeutics, Inc., ... Levy, PhD, Chief Executive Officer, and David Socks, President ... and Company 32nd Annual Health Care Conference on Tuesday, ... Boston Marriott Copley Place. About Incline ...
... February 29, 2012 TREM Rx, Inc., a biotechnology company ... the skin, announced today the results of an in vivo ... cells of the immune system called TREMs (T Resident Effector ... immune response that is far stronger than memory T cells ...
Cached Biology Technology:Berg Diagnostics Receives CLIA Certification and Launches Novel Vitamin D Assay 2Discovery in Nature elucidates immune cells in skin and supports novel vaccine approach 2Discovery in Nature elucidates immune cells in skin and supports novel vaccine approach 3
(Date:11/5/2014)... Redmond has dedicated his career to understanding the ... general audience. , As deputy director and regional ... Nevada,s Desert Research Institute, Redmond has more than ... and dissemination of climate data to the general ... in San Francisco on December 15-19, 2014 the ...
(Date:11/4/2014)... SALT LAKE CITY, Nov. 5, 2014 – University of ... uses enzymes to help jet fuel produce electricity without ... can be used to power portable electronics, off-grid power ... appears online today in the American Chemical Society journal ... into electricity through a chemical reaction between a fuel ...
(Date:11/4/2014)... PA) – Temple University School of Medicine announced ... winner, an initiative funded by the Bill & ... Professor of Obstetrics, Gynecology and Reproductive Sciences; and ... Temple University School of Medicine will pursue an ... "Maternal Blood Biomarkers to Assess Fetal Neurodevelopment.", Grand ...
Breaking Biology News(10 mins):Nevada climatologist to be honored at AGU Fall Meeting for lifetime of public outreach 2Jet-fueled electricity at room temperature 2Temple University School of Medicine receives Grand Challenges Explorations grant 2
... finds human-caused climate change may have little impact ... host of recent studies that predict their widespread ... findings, which appear in the journal Global ... of a creature thought to be doomed: ...
... to Research Careers) Program has announced the travel award ... Annual Meeting in Cancun, Mexico from June 16-20, 2013. ... students, postdoctorates and scientists from underrepresented groups into the ... the participation of young scientists at the SDB 2013 ...
... cellular layer lining the body,s blood vessels, is ... in thickness, this super-tenuous structure routinely withstands blood ... create a unique and highly dynamic barrier that ... the body,s circulatory system. It,s also extremely ...
Cached Biology News:Climate change may have little impact on tropical lizards 2Endothelium, heal thyself 2Endothelium, heal thyself 3Endothelium, heal thyself 4
Contained in EZ-Tn5™ Kits and are available separately for sequencing of an insertion site....
Request Info...
Rabbit polyclonal to Syntrophin alpha 1 ( Abpromise for all tested applications). entrezGeneID: 6640 SwissProtID: Q13424...
Mouse monoclonal [4i97] to HLA Class 1 A25 ( Abpromise for all tested applications). Antigen: Full length protein (Human): HLA Class 1 Antigen-A25. Swiss Protein ID: P18462...
Biology Products: